ArticleThe British journal of oral & maxillofacial surgery2021
COVID-19 associated mucormycosis (CAM) in India: a formidable challenge.
Article in The British journal of oral & maxillofacial surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 90 citations in OpenAlex.
- Active Surveillance for Invasive Mold Disease - Four Hospitals, Atlanta, Georgia, 2020-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026Article
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Molecular Assays Versus Mycological Methods for Diagnosis of Rhino Orbital Mucormycosis: Analysis of 120 Clinical Specimens from COVID-19 Patients.Mycopathologia · 2025Article
- Natural Isatin Derivatives Against Black Fungus: In Silico Studies.Current microbiology · 2024Article
- Article
- COVID-19-Associated Rhino-Orbital Mucormycosis: Histological and Electron Microscopy Characteristics.Diagnostics (Basel, Switzerland) · 2024Article
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- Association of COVID with Mycosis in General.Infectious disorders drug targets · 2024Review
- Clinical, Demographic, and Oral Presentations of COVID-19 Associated Mucormycosis from a Tertiary Care Hospital in India: A Cross-Sectional Study.Journal of maxillofacial and oral surgery · 2023Article
- Article
- Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review.Current microbiology · 2023Review
- Black fungus outbreak in India - A direct consequence of COVID-19 surge: A myth or reality.Gondwana research : international geoscience journal · 2023Article
- Maxillary mucormycosis and concurrent osteomyelitis in a post-COVID-19 patient with new onset diabetes mellitus.Proceedings (Baylor University. Medical Center) · 2023Article
- Potential inhibitory activity of phytoconstituents against black fungus:Computational toxicology (Amsterdam, Netherlands) · 2022Article
- Article
- Management of Mucormycosis in Post COVID-19 Patients and Its Outcome in a Tertiary Care Center: Our Experience.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- SARS-CoV-19-associated Rhino-orbital and cerebral mucormycosis: clinical and radiological presentations.Medical mycology · 2022Article
- COVID-19-Associated Mucormycosis: An Opportunistic Fungal Infection. A Case Series and Review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Review
- An ubiquitous entity of post-COVID rhinomaxillary mucormycosis.Journal of family medicine and primary care · 2022Article
- Predictors for mucormycosis in COVID era: A case-control study from Gujarat.Journal of family medicine and primary care · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Together with the ongoing serious COVID-19 second wave in India, a serious fungal infection, mucormycosis has been increasingly found in COVID-19-recovered patients. Colloquially known as 'black fungus', mucormycosis commonly causes necrosis in the head and neck including the nose, paranasal sinuses, orbits, and facial bones, with possible intracranial spread. The disease causes high morbidity and mortality given that it progresses rapidly and diagnosis is often delayed. Given the sheer magnitude of the outbreak, the Indian Health Ministry has advised all states to declare mucormycosis an epidemic. Typically, the disease has been found to be linked to COVID-19 infections caused by the B.1.617.2 (Delta) variant, which has spread rapidly throughout the country. This variant has already become a cause for global concern, having spread to at least 40 countries, including the USA and UK. We present the findings of a study conducted on COVID-19 associated mucormycosis (CAM) patients, and discuss the associated risk factors to raise awareness for OMFS colleagues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.